O’Melveny Worldwide

Fan Wu is an associate in O’Melveny’s Beijing office and a member of the Corporate Finance and Capital Markets Practice. Previously, Fan focused her practice on intellectual property, especially on patent prosecution, trademark applications, post-grant proceedings, pre-litigation analysis, IP infringement, IP transactions, and IP due diligence on behalf of domestic and foreign clients.

Capital Markets:

  • Adlai Nortye Ltd. (NASDAQ: ANL) in its approximately US$100 million IPO on the Nasdaq
  • Jenscare Scientific Co., Ltd. in its IPO and listing on the Hong Kong Stock Exchange

Intellectual Property:

  • a global leading biopharma company on protecting the potential patent rights of its COVID-19 mRNA vaccine in mainland China, including providing advice on non-infringement and patentability
  • a global leading food company on collaborating with local partners in China, especially providing advice on IP related issues
  • a leading Singapore company in maternal and infant products industry, including providing advice on filing patent applications and patent infringement risks in China
  • an affiliate of a reputable UK university on cooperating with Chinese local partners in research and development, especially on the IP related issues
  • a UK pharmaceutical company on its collaboration with a CRO company in China, including providing advice on patent infringement risks
  • a German private equity on its acquisition of Bock Germany particularly the Chinese aspects, including IP due diligence of trademarks, patents, and domain names
  • a global leading daily necessity company on protecting its trademark rights in China, including providing advice on filing trademark applications, filing non-use cancellations against trademark registered by third parties, and potential trademark infringement risks
  • a vitamin and nutrition beauty manufacturer on protecting its trademark rights in China, including providing advice on trademark applications, and fighting against potential infringers
  • major and start-up companies, universities, and government departments on prosecuting patent applications mainly in biotechnological and pharmaceutical fields before CNIPA
  • a global leading pharmaceutical company on defending the validity of its patents related to a vaccine before Reexamination and Invalidation Department of CNIPA and Beijing Intellectual Property Court
  • a pharmaceutical company on analyzing the validity of a crystal form patent, and representing the client in invalidating the same before Reexamination and Invalidation Department of CNIPA
  • a bio-tech company on prosecuting patents related to Antibody-Drug-Conjugate preparation method, and representing them in a freedom-to-operate analysis
  • a company in dentistry on analyzing non-infringement and validity of a concerned patent related to dental implants, and representing the client in a freedom-to-operate analysis


  • English
  • Mandarin Chinese


  • New York


  • Suffolk University Law School, Juris Doctor, cum laude
  • Illinois Institute of Technology, MSc in Biology Science
  • Shandong University, BSc in Biology Science

Professional Activities

Bar Exams

  • Passed Massachusetts Bar Exam
  • Passed Chinese Patent Bar Exam


  • “Enhancement of desulfurization activity by enzymes of the Rhodococcus dsz operon through co-expression of high sulfur peptides and directed evolution.” Fuel 112 (2013): 385-390.
  • “Enhancement of Microbial Biodesulfurization via Genetic Engineering and Adaptive Evolution.” Plos One, DOI:10.1371/Journal, pone. 01688333 (2017): 1-20.